Intrinsic Value of S&P & Nasdaq Contact Us

Exelixis, Inc. EXEL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
83/100
6/7 Pass
SharesGrow Intrinsic Value
$125.10
+172.8%
Analyst Price Target
$44.11
-3.8%

Exelixis, Inc. (EXEL) — Analyst outlook / Analyst consensus target is. Based on 32 analyst ratings, the consensus is bullish — 16 Buy, 16 Hold.

The consensus price target is $44.11 (low: $30.00, high: $54.00), representing a downside of 3.8% from the current price $45.86.

Analysts estimate Earnings Per Share (EPS) of $1.15 and revenue of $2.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $1.80 vs est $1.15 (beat +56.1%). 2025: actual $2.88 vs est $1.73 (beat +66.4%). Analyst accuracy: 62%.

EXEL Stock — 12-Month Price Forecast

$44.11
▼ -3.82% Downside
Average Price Target
Based on 32 Wall Street analysts offering 12-month price targets for Exelixis, Inc., the average price target is $44.11, with a high forecast of $54.00, and a low forecast of $30.00.
The average price target represents a -3.82% change from the last price of $45.86.
Highest Price Target
$54.00
Average Price Target
$44.11
Lowest Price Target
$30.00

EXEL Analyst Ratings

Buy
32
Ratings
16 Buy
16 Hold
Based on 32 analysts giving stock ratings to Exelixis, Inc. in the past 3 months
Rating breakdown
Buy
16 50%
Hold
16 50%
50%
Buy
16 analysts
50%
Hold
16 analysts
0%
Sell
0 analysts

EPS Estimates — EXEL

62%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual $1.80 vs Est $1.15 ▲ 35.9% off
2025 Actual $2.88 vs Est $1.73 ▲ 39.9% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.

Revenue Estimates — EXEL

93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $2.169B vs Est $2.014B ▲ 7.1% off
2025 Actual $2.320B vs Est $2.165B ▲ 6.7% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message